

WHSSC STATEMENT OF SUPPORT

CVUHB has had a number of discussions with WHSSC with regards to the vision for the programme, the clinical transformation, and its impact on the tertiary and quaternary clinical services. It is expected that the PBC will be discussed formally in a joint meeting on the 9th of March, which will be minuted.

In advance of this meeting, WHSSC have provided the following interim statement of support:

“Specialist Services

In Wales the Welsh Health Specialist Services Committee (WHSSC) is responsible for commissioning a defined range of specialist and highly specialist services on behalf of the seven Health Boards. They aim to ensure equitable access to safe, effective and sustainable services but also wish to ensure services are delivered as close to home as possible. WHSSC have a range of contracts with both English and Welsh providers, predominantly though specialist services for south Wales’ residents are commissioned from Cardiff and the Vale University Health Board and Swansea Bay University Health Board. The contract that WHSSC hold with Cardiff and the Vale Health University Health Board is significantly their largest contract and for 2020-21 was c£240m.

WHSSC note that the demand for specialised services continues to increase as advances in medical technology offer treatment where previously none were available. The aspiration of WHSSC is to bring more services into Wales where it is safe and sustainable to do this and the development of UHW2 offers this opportunity to increase delivery of specialist services within Wales.

The collaboration with Swansea Bay University Health Board has been previously described, but the development of UHW2 also offers other opportunities to deliver an enhanced portfolio of specialised services;

- *Recognising that advances in medical technology and treatment continues to grow and demand for specialist services continues to increase CAV could deliver more specialist services to meet this demand. Particularly linking with the Life Sciences eco-system and building on the already successful services around genetics, CAR-T and the delivery of other Advanced Medicinal Therapeutic Products (ATMPs).*
- *Using the newly developed facilities and services to bring services into south Wales that are currently commissioned from Trusts in NHS England such as pulmonary hypertension services.*
- *Working collaboratively with Trusts in NHS England in a Networked way to potentially act as a hub for a range of specialist services.*
- *Development of a unit for Rare Diseases ensuring delivery of the newly published Rare Diseases Strategy across the UK. CAV is ideally placed to significantly enhance services and experience for both child and adult patients living with a rare disease. This would clearly need to be in collaboration with NHS England.*
- *Increasing delivery of specialist services will also bring opportunities for increasing research in specialist services and could lead to national and international collaboration on a range of services.”*